Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), but a less favorable effect on lipids. Aim of this study was to evaluate the impact on lipids of switching from rilpivirine (RPV)/ emtricitabine (FTC)/TDF to RPV/FTC/TAF in a large cohort of HIV-1 infected patients.
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: different effects in different patients populations : results from a large observational study / L. Taramasso, A. Di Biagio, N. Riccardi, F. Briano, E. Di Filippo, L. Comi, S. Mora, M. Giacomini, A. Gori, F. Maggiolo - In: ICAR 2019[s.l] : Icar, 2019. - pp. 51-51 (( Intervento presentato al 11. convegno Italian Conference on AIDS and Antiviral Research tenutosi a Milano nel 2019.
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: different effects in different patients populations : results from a large observational study
L. Taramasso;N. Riccardi;A. Gori;
2019
Abstract
Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), but a less favorable effect on lipids. Aim of this study was to evaluate the impact on lipids of switching from rilpivirine (RPV)/ emtricitabine (FTC)/TDF to RPV/FTC/TAF in a large cohort of HIV-1 infected patients.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Taramasso_19.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
201.05 kB
Formato
Adobe PDF
|
201.05 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
